Details

Autor(en) / Beteiligte

• Adamowicz, David H.
• Wu, Tsung-Chin
• Daly, Rebecca
• Irwin, Michael R.
• Jeste, Dilip V.
• Tu, Xin M.
• Eyler, Lisa T.
• Lee, Ellen E.

Titel

Executive functioning trajectories and their prospective association with inflammatory biomarkers in schizophrenia and non-psychiatric comparison participants

Ist Teil von

• Progress in neuro-psychopharmacology & biological psychiatry, 2024-01, Vol.128, p.110866-110866, Article 110866

Ort / Verlag

England: Elsevier Inc

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Cognitive change in people with schizophrenia (PwS) is challenging to assess, but important to understand. Previous studies with limited age ranges and follow-up were subject to practice effects. Controlling for practice effects in a well-established cohort, we examined executive functioning trajectories and their association with inflammatory biomarkers, hypothesizing that PwS will have worsening executive functioning over time compared to non-psychiatric comparison participants (NCs), predicted by higher baseline inflammation with a stronger relationship in PwS than NCs. Executive functioning was assessed in 350 participants (n = 186 PwS, 164 NCs) at 12–16-month intervals (0 to 7 follow-up visits). Inflammatory biomarkers at baseline included high sensitivity C-Reactive Protein (hs-CRP), Interferon-gamma, Tumor Necrosis Factor (TNF)-alpha, and Interleukin(IL)-6, −8, and − 10. Executive functioning trajectories across diagnostic groups were estimated using a linear mixed-effects model controlling for age, sex, race/ethnicity, and education level, with additional models to assess prediction by baseline inflammation. Over 4.4 years average follow-up, improvements in executive functioning were attenuated in PwS and older participants. Controlling for practice effects negated improvements, revealing declines among highly educated participants regardless of diagnosis. Higher baseline hs-CRP predicted worse executive functioning only among NCs, while TNF-alpha was predictive of change in all participants only after controlling for practice effects. Only the main effect of hs-CRP on executive function was significant after adjusting for multiple comparisons. None of the other inflammatory biomarkers predicted executive functioning or trajectories of performance among study participants. Systemic inflammation as reflected by baseline inflammatory biomarker levels did not predict longitudinal declines in executive functioning. Additional studies examining the temporal dynamics of inflammation and cognition in PwS will help further clarify their relationship and associated mechanisms. •Higher baseline TNF-alpha predicted worse cognition over 4.4 years, but not after controlling for multiple comparisons.•After controlling for practice effects, people with schizophrenia did not have accelerated decline in executive functioning.•Older age and less education were associated with worse cognitive functioning.